Cantor Fitzgerald Has Weak Forecast for ACRS FY2025 Earnings
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) – Equities researchers at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for Aclaris Therapeutics in a research report issued on Tuesday, March 18th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biotechnology company will post earnings per share of ($0.62) for the year, down […]
More Stories
US Property Taxes Grow 3 Percent on Average in 2025, Outpacing Inflation
By Rob Sabo Property taxes are rising across the United States and, on average, have outpaced inflation. Homeowners in 2025...
Shane Lowry Makes Golf History With His 2nd Masters Hole-in-One
By Ross Kelly There are millions of casual golfers around the world who dream some day of recording an ace...
Treasury, IRS Propose Rules for 1 Percent Remittance Tax on Some Money Sent to Foreign Countries
By Naveen Athrappully The Internal Revenue Service and the Department of the Treasury proposed regulations on Friday regarding the new...
Hezbollah Leader Says Group Would Continue to Fight Israel After Strikes
By Jack Phillips The leader of Lebanese terrorist organization Hezbollah has said that his group would continue to fight Israel,...
IBM to Pay $17 Million to Settle Allegations of Discrimination
By Jacki Thrapp IBM will pay millions of dollars to resolve allegations that it failed to comply with anti-discrimination requirements...
Trump Says US ‘Loading up the Ships’ Ahead of Iran Talks, Signals Military Option If Diplomacy Fails
By Tom Ozimek President Donald Trump said the United States is preparing military options if negotiations with Iran fail to...